Dr. Iman Imanirad

About Dr. Imanirad

Dr. Imanirad leads clinical and research efforts focused on gastrointestinal oncology with special expertise in peritoneal cancers and mesothelioma. He combines advanced research with personalized care to offer patients the latest treatment options for these complex diseases. He believes clear communication is essential to help patients understand their diagnosis and treatment choices.

Close Button

Full Name

Diagnosis Please Select Mesothelioma Asbestosis Lung Cancer No Diagnosis Other Unknown

Zip Code

Email

Phone Number

Preferred Method of Contact Please Select Call Text

Message

Full Name

By clicking Get Connected Now, you agree to be contacted by Asbestos.com’s Patient Advocates with health-related information and services via call, text/SMS using an automated dialing platform and/or email at the telephone number and/or email you provided. Std. msg./data rates apply and your consent to such contact/marketing is not required for purchase of services. You also agree to our Privacy Policy and Terms of Service, including the agreement to arbitrate disputes.

Get Connected Now

Medical Education & Expertise

• Moffitt Cancer Center 
• University of South Florida College of Medicine (Professor of Oncology)
• Tallahassee Memorial Hospital (Medical Oncologist and Hematologist)
  University of Florida College of Medicine (Fellowship)
• University of Florida College of Medicine (Residency)
• Saba University School of Medicine (M.D.)

Associations, Awards & Recognition

• Board Certified in Internal Medicine, Hematology and Medical Oncology, American Board of Internal Medicine
• Fellow of the Year Award
• Moffitt High Performer Award, 2019
• Most Outstanding Fellow Award 

Why Choose Dr. Imanirad for Peritoneal Mesothelioma?

Dr. Imanirad has specialized expertise in peritoneal mesothelioma treatment. He stays current with emerging clinical trials and targeted treatments designed specifically for this rare cancer type. His experience with gastrointestinal cancers gives him a unique perspective on managing the complexities of mesothelioma.

Patients appreciate Dr. Imanirad’s commitment to personalized care. He takes time to understand each person’s condition and priorities, crafting tailored treatment plans. His patients benefit from his clinical skill and dedication to providing clear guidance and support throughout their care.

Publications of Dr. Imanirad

Imanirad, I. et al. (2025, May 28). Association of Pathologic Response and Adjuvant Chemotherapy with Survival in Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy. Retrieved from https://pubmed.ncbi.nlm.nih.gov/40507279/

Imanirad, I. et al. (2025, May). Incomplete Resection Is Twice as Likely in Locally Advanced Mucinous Compared to Nonmucinous Rectal Adenocarcinoma: A National Propensity-Matched Analysis. Retrieved from https://pubmed.ncbi.nlm.nih.gov/39658830/

Imanirad, I. et al. (2024, November). TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial. Retrieved from https://pubmed.ncbi.nlm.nih.gov/39244627/

Imanirad, I. et al. (2023, February 1). Tumor Response-speed Heterogeneity as a Novel Prognostic Factor in Patients With Metastatic Colorectal Cancer. Retrieved from https://pubmed.ncbi.nlm.nih.gov/36606664/

Imanirad, I. et al. (2021, February 25). Pretreatment CT and PET radiomics predicting rectal cancer patients in response to neoadjuvant chemoradiotherapy. Retrieved from https://pubmed.ncbi.nlm.nih.gov/33948299/